Tracking a rare disease Drug's Real-World impact
NCT ID NCT05469789
Summary
This study is observing 50 patients in the UK who have hereditary angioedema (HAE) and are taking the drug lanadelumab as part of their normal care. The main goal is to compare how many HAE attacks patients experience in the year before starting the drug to the number they have in the two years after starting it. Researchers are collecting data from patient diaries, medical records, and regular check-ins to understand the drug's real-world effectiveness and its impact on patients' lives.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Health NHS Trust
London, England, E1 1BB, United Kingdom
Conditions
Explore the condition pages connected to this study.